Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus BioSciences, Inc. - Common Stock (NQ:CHRS)

0.8057 +0.0057 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Coherus BioSciences Announces CFO Transition Plans
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
From Coherus BioSciences, Inc.
Via GlobeNewswire
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
What 6 Analyst Ratings Have To Say About Coherus BioSciences
Via Benzinga
Analyst Ratings for Coherus BioSciences
Via Benzinga
Why Coherus Biosciences Stock Dropped Today
Coherus missed estimates for the third quarter and lowered its full-year outlook. 
Via The Motley Fool
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Was Plummeting This Week
The company has been punished harshly for a worse-than-expected quarter. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical... 
Via Benzinga
Coherus BioSciences's Earnings: A Preview
Via Benzinga
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. 
Via InvestorPlace
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
From Coherus BioSciences, Inc.
Via GlobeNewswire
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
Via Talk Markets
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences to Participate at Upcoming November Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
BP, V.F. Corporation, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mostly higher this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
From Coherus BioSciences, Inc.
Via GlobeNewswire
Why Coherus BioSciences Stock Soared Today
Coherus and Junshi Biosciences announced the long-awaited FDA approval of NPC drug Loqtorzi. Here's what investors need to know. 
Via The Motley Fool
Exposures Product Safety
What's Going On With Coherus BioSciences Stock?
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Monday after the company announced the FDA-approval of Loqtorzi in all lines of treatment for 
Via Benzinga
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.